eligibility_summary
Adults 18–60 (≥30 kg) with hematologic disease, any sex/race, willing to undergo haploidentical HSCT, and able to provide informed consent (or proxy if unable). Exclude severe heart/liver/kidney/pancreas dysfunction, intolerance to CD25 mAb, refusal of allo-HSCT, safety-risking conditions (life-threatening disease, drug dependence, uncontrolled mental/cognitive disorders), similar trial in past 3 months, or investigator-deemed unsuitable.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
manual_review_required
ai_summary
Phase 2, parallel-arm prevention trial in haploidentical HSCT. All patients receive low‑dose anti‑thymocyte globulin (ATG 7.5 mg/kg pre‑HSCT). Experimental arm adds a humanized anti‑CD25 monoclonal antibody (1 mg/kg IV on days +4 and +7). Drugs/mechanisms: • Anti‑CD25 mAb (type: monoclonal antibody) binds IL‑2 receptor alpha (CD25) on activated T cells (and Tregs), blocking IL‑2–JAK/STAT signaling to curb proliferation, survival, and cytokine production of alloreactive effector T cells that cause GVHD, may also modulate Treg function. • ATG (type: polyclonal immunoglobulin) depletes T cells via complement-mediated lysis/apoptosis and immune modulation. Targets/pathways: donor/host CD4+ and CD8+ T cells, IL‑2/IL‑2R (CD25) axis with downstream STAT5, GVHD effector T‑cell responses.